. Author manuscript; available in PMC: 2014 Aug 1.

Published in final edited form as: Am J Ophthalmol. 2013 May 10;156(2):283–292.e1. doi: 10.1016/j.ajo.2013.03.021

TABLE 5.

Pathologic Changes From Baseline at 12 Months in Patients Receiving Encapsulated Cell Intraocular Implants for Retinitis Pigmentosa

Endpoint	CNTF3		CNTF4
Endpoint	Low-Dose Implant/Sham	High-Dose Implant/Sham	Low-Dose Implant/Sham	High-Dose Implant/Sham
Change in macular edema total	18/18	36/36	19/19	47/47
No	15 (83%)/15 (83%)	25 (69%)/26 (72%)	10 (53%)/9 (47%)	17 (36%)/16 (34%)
Yes	3 (17%)/3 (17%)	11 (31%)/10 (28%)	9 (47%)/10 (53%)	30 (64%)/31 (66%)
Change in epiretinal membrane total	18/19	41/39	19/19	47/46
No	7 (39%)/5 (26%)	6 (15%)/10 (26%)	11 (58%)/10 (53%)	21 (45%)/23 (50%)
Yes	11 (61%)/14 (74%)	35 (85%)/29 (74%)	8 (42%)/9 (47%)	26 (55%)/23 (50%)
Change in vitreomacular attachment total	17/18	36/37	19/19	47/45
No	15 (88%)/18 (100%)	32 (89%)/33 (89%)	18 (95%)/16 (84%)	45 (96%)/42 (93%)
Yes	2 (12%)/0 (0%)	4 (11%)/4 (11%)	1 (5%)/3 (16%)	2 (4%)/3 (7%)

CNTF3 = ciliary neurotrophic factor for late-stage retinitis pigmentosa study 3; CNTF4 = ciliary neurotrophic factor for early-stage retinitis pigmentosa study 4.